FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020699761> ?p ?o ?g. }

• W2020699761 endingPage "300" @default.
• W2020699761 startingPage "295" @default.
• W2020699761 abstract "Chronic renal failure causes left ventricular hypertrophy, but the molecular mechanisms involved remain unknown. We, therefore, investigated whether the mineralocorticoid receptor is implicated in the cardiac hypertrophy observed in uremic rats and whether mineralocorticoid receptor blockade could be protective in chronic renal failure. Experimental groups were: control rats, uremic rats (NPX) with 5/6 nephrectomy (5 weeks), and NPX rats fed with spironolactone for 5 weeks. Systolic blood pressure was increased in both NPX rats and NPX rats fed with spironolactone for 5 weeks. Echocardiography revealed concentric left ventricular hypertrophy in uremia, which was attenuated by spironolactone. Enlarged cardiomyocyte size was observed in both left and right ventricles of NPX rats, an effect that was prevented by spironolactone. Mineralocorticoid receptor antagonism attenuated the increase of ventricular brain natriuretic peptide mRNA levels induced by nephrectomy. Left ventricular gene expressions of aldosterone synthase, mineralocorticoid receptor, and hydroxysteroid dehydrogenase type 2 were the same in the 3 groups, whereas gene expression of the glucocorticoid receptor was significantly diminished in chronic renal failure rats. No significant differences in cardiac aldosterone were observed between control rats and NPX rats, although NPX rats fed with spironolactone for 5 weeks showed increased plasma aldosterone levels. However, a significant increase in serum and glucocorticoid-inducible kinase-1 mRNA expression and protein was present in the NPX group; spironolactone treatment significantly reduced serum and glucocorticoid-inducible kinase-1 mRNA and protein in the left ventricle. Uremic rats exhibited a significant increase of superoxide production and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits expression (NOX-2, NOX-4, and p47 phox ) in the left ventricle, which was prevented by the mineralocorticoid receptor antagonist. Our findings provide evidence of the beneficial effects of spironolactone in cardiac hypertrophy and cardiac oxidative stress in chronic renal failure." @default.
• W2020699761 created "2016-06-24" @default.
• W2020699761 creator A5008897668 @default.
• W2020699761 creator A5019656947 @default.
• W2020699761 creator A5023471998 @default.
• W2020699761 creator A5050582000 @default.
• W2020699761 creator A5057435596 @default.
• W2020699761 creator A5077441582 @default.
• W2020699761 creator A5078981863 @default.
• W2020699761 creator A5089394054 @default.
• W2020699761 date "2008-08-01" @default.
• W2020699761 modified "2023-10-04" @default.
• W2020699761 title "Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats" @default.
• W2020699761 cites W1558440797 @default.
• W2020699761 cites W1969968096 @default.
• W2020699761 cites W1987399592 @default.
• W2020699761 cites W2001416766 @default.
• W2020699761 cites W2002175243 @default.
• W2020699761 cites W2002225053 @default.
• W2020699761 cites W2017884988 @default.
• W2020699761 cites W2019216135 @default.
• W2020699761 cites W2030020451 @default.
• W2020699761 cites W2042022260 @default.
• W2020699761 cites W2048975894 @default.
• W2020699761 cites W2050427659 @default.
• W2020699761 cites W2054559423 @default.
• W2020699761 cites W2069972175 @default.
• W2020699761 cites W2075141928 @default.
• W2020699761 cites W2076805069 @default.
• W2020699761 cites W2082151580 @default.
• W2020699761 cites W2085134546 @default.
• W2020699761 cites W2085822292 @default.
• W2020699761 cites W2086392932 @default.
• W2020699761 cites W2093131177 @default.
• W2020699761 cites W2096111588 @default.
• W2020699761 cites W2104846033 @default.
• W2020699761 cites W2108548563 @default.
• W2020699761 cites W2119822557 @default.
• W2020699761 cites W2128777135 @default.
• W2020699761 cites W2131647357 @default.
• W2020699761 cites W2134912211 @default.
• W2020699761 cites W2144218780 @default.
• W2020699761 cites W2162193671 @default.
• W2020699761 cites W2162607913 @default.
• W2020699761 cites W2168602041 @default.
• W2020699761 cites W2169494292 @default.
• W2020699761 cites W2323458614 @default.
• W2020699761 cites W70952215 @default.
• W2020699761 doi "https://doi.org/10.1161/hypertensionaha.107.109645" @default.
• W2020699761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18591458" @default.
• W2020699761 hasPublicationYear "2008" @default.
• W2020699761 type Work @default.
• W2020699761 sameAs 2020699761 @default.
• W2020699761 citedByCount "58" @default.
• W2020699761 countsByYear W20206997612012 @default.
• W2020699761 countsByYear W20206997612013 @default.
• W2020699761 countsByYear W20206997612014 @default.
• W2020699761 countsByYear W20206997612015 @default.
• W2020699761 countsByYear W20206997612016 @default.
• W2020699761 countsByYear W20206997612017 @default.
• W2020699761 countsByYear W20206997612018 @default.
• W2020699761 countsByYear W20206997612019 @default.
• W2020699761 countsByYear W20206997612020 @default.
• W2020699761 countsByYear W20206997612021 @default.
• W2020699761 countsByYear W20206997612022 @default.
• W2020699761 crossrefType "journal-article" @default.
• W2020699761 hasAuthorship W2020699761A5008897668 @default.
• W2020699761 hasAuthorship W2020699761A5019656947 @default.
• W2020699761 hasAuthorship W2020699761A5023471998 @default.
• W2020699761 hasAuthorship W2020699761A5050582000 @default.
• W2020699761 hasAuthorship W2020699761A5057435596 @default.
• W2020699761 hasAuthorship W2020699761A5077441582 @default.
• W2020699761 hasAuthorship W2020699761A5078981863 @default.
• W2020699761 hasAuthorship W2020699761A5089394054 @default.
• W2020699761 hasBestOaLocation W20206997611 @default.
• W2020699761 hasConcept C126322002 @default.
• W2020699761 hasConcept C134018914 @default.
• W2020699761 hasConcept C189135053 @default.
• W2020699761 hasConcept C2776002628 @default.
• W2020699761 hasConcept C2776069600 @default.
• W2020699761 hasConcept C2776379505 @default.
• W2020699761 hasConcept C2778525890 @default.
• W2020699761 hasConcept C2780072264 @default.
• W2020699761 hasConcept C71924100 @default.
• W2020699761 hasConcept C84393581 @default.
• W2020699761 hasConceptScore W2020699761C126322002 @default.
• W2020699761 hasConceptScore W2020699761C134018914 @default.
• W2020699761 hasConceptScore W2020699761C189135053 @default.
• W2020699761 hasConceptScore W2020699761C2776002628 @default.
• W2020699761 hasConceptScore W2020699761C2776069600 @default.
• W2020699761 hasConceptScore W2020699761C2776379505 @default.
• W2020699761 hasConceptScore W2020699761C2778525890 @default.
• W2020699761 hasConceptScore W2020699761C2780072264 @default.
• W2020699761 hasConceptScore W2020699761C71924100 @default.
• W2020699761 hasConceptScore W2020699761C84393581 @default.
• W2020699761 hasIssue "2" @default.
• W2020699761 hasLocation W20206997611 @default.
• W2020699761 hasLocation W20206997612 @default.

• next